Vector Laboratories is closed for the President’s Day on Monday, February 19th. We will be back in the office on Tuesday, February 20th.
We will respond to emails upon our return. Have a wonderful day.

Newsroom

NEW YORK — Vector Laboratories said Tuesday that it has partnered with Swedish life science…

More than 80 years later, methods to detect and visualise proteins in biological samples continue to advance, driving the discovery and development of novel therapies and diagnostics. New capabilities empower researchers to gain deep, high-resolution insights into biological processes and disease markers.

Since biotech valuations on public markets peaked in September 2021, the sector has had to contend with reduced financing availability and harsher conditions for deal-making.

Lisa Sellers is the CEO of Vector Laboratories, and she is passionate about staying ahead of the pharma trends. She discovered a passion for science after her very first chemistry lesson and found the subject came easily to her. To find out more about her and how she overcame the challenges of being the first woman scientist in her lab and finding her way in a male-dominated industry.

The ability to combine the activity of a biomolecule with the activity of another entity through bioconjugation has been critical to basic research and discovery for decades.

Authority Magazine. An Interview with Karen Mangia. Pamela James, PhD, Vice President, Product discusses the importance of leaders becoming better coaches.

Pamela James, PhD, Vice President, Product  recently spoke to Labcompare about the importance of glycans, technologies to advance glycan research and how glycobiology is posed to impact future health and disease research.

CEO Lisa V. Sellers, PhD discusses how companies should explore the importance of cultural alignment and employee experience during company acquisitions while providing strategies for successful integration to prevent revenue losses and boost the chances of a successful merger.

Lisa V. Sellers, PhD, CEO of Vector Laboratories, discusses strategies for addressing female underrepresentation in STEM fields, emphasizing the role of businesses in sparking early interest in STEM among girls.

In this article, Pamela James, PhD, Vice President, Product, provides a basic overview of the fundamentals of glycobiology and its role in health and disease, reviews the characteristics that make glycans and glycosylation strong potential candidates for biomarker discovery, and discusses the latest advances in research methods powering new applications for glycobiology.

 

CEO Lisa V. Sellers, PhD discusses the importance of mentoring underrepresented students in STEM.

CEO Lisa V Sellers, PhD joins other leaders as they share their forecasts as the industry continues to push through challenges.

This article walks through some of the foundational developments in the field of glycobiology that have powered the progress made in 2022 and what these advancements signal for the future.

No one can tell you exactly how to give a good talk, but learning the basics and identifying personal touches can help get you there. In this article, Vector Laboratories CEO, Lisa V. Sellers, PhD, shares some ideas have shaped her own presentation style and tips for finding your unique voice.

Authority Magazine. An Interview with Candice Georgiadis. CEO Lisa V Sellers of Vector Laboratories on the five leadership lessons she learned from her experience

Across scientific disciplines, many researchers are experiencing difficulty when trying to replicate previously observed experimental results. In this article, Pamela James discusses how labs and vendors can work together to improve reproducibility.

Check out this article in the European Biopharameutical Review about the role of the glycome in cancer diagnosis and treatment by our very own Pamela James who explains glycobiology’s role in supporting scientists who are doing incredible things in the field of oncology.

Seeing a company you believe in turn things around is truly rewarding. Here are six key tips from Lisa Sellers, PhD, CEO, to guide you on the journey to transform a mature business as featured on Forbes.

San Francisco Business Times. Lisa V. Sellers, PhD, CEO of Vector Laboratories, shares her insights and lessons learned for company relocation.

Silicon Valley Business Journal. Lisa Sellers, PhD, CEO of Vector Laboratories, was nominated and selected to be in the 2022 Class of Women of Influence. Read her interview. 

Biocompare. Erika Leonard, Director of Quality Control and R&D, Vector Laboratories, provides insights into common IHC issues and ways of resolving them. 

Genetic Engineering & Biotechnology News. The new funding, backed by private equity firm Thompson Street Capital Partners, enables Vector Laboratories to embark upon an acquisition strategy while accelerating the commercialization of innovative labeling and detection technologies for immunohistochemistry, immunofluorescence, glycobiology, and bioconjugation.

Endpoint News. Vector announced a $124 million cash buyout backed by private equity firm Thompson Street Capital Partners on Tuesday to fund its expansion in protein detection. 

Authority Magazine. An Interview With Charlie Katz. Lisa V Sellers of Vector Laboratories on the five things you need to succeed as a senior executive.

NEWARK, Calif. (January 30, 2024) –

Introducing innovative tools combining proteomics and glycomics within the spatial context, overcoming previous challenges and advancing the possibilities for biopharma discovery.

Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, and Navinci Diagnostics, leader of innovative in situ proximity ligation assay-based solutions, today announced that they have signed an agreement…

NEWARK, Calif. (July 17, 2023) –

Acquisition expands customers’ ability to accelerate their advanced bioconjugate and payload delivery design innovation

Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, today announced the acquisition of Quanta BioDesign

NEWARK, Calif. (March 2, 2023) –

Acquisition contributes to long-term growth strategy of accelerating commercialization of innovative labeling and detection technologies

Vector Laboratories, the pioneer of innovative proteomic and glycomic research solutions, today announced the acquisitions of

NEWARK, Calif. (August 2, 2022) – Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, announced today that it has achieved ISO 9001:2015 certification of its new facility in Newark, California. This designation, renewed in May 2022 when the company moved its headquarters and manufacturing facilities, certifies a high level of quality assurance and consistency and is particularly important for Vector Laboratories custom…

NEWARK, Calif. (July 26, 2022) –

Diverse and deep financial and commercial experience will help lead Vector Laboratories’ ongoing expansion strategy

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today announced that Vatea Herman, CPA and Kenny Drew, MS joined the Executive Team as Chief Financial Officer and Vice President, Commercial, respectively. …

NEWARK, Calif. (July 19, 2022) –

Offers a new, promising frontier to advance research and exploration of diseased and healthy tissue

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today announced the la…

NEWARK, Calif. (March 29, 2022) –

Woo bringing key manufacturing experience and turnaround time reductions to proteomic and glycomic-focused company

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today announced that Kum Ming Woo has joined its executive…

BURLINGAME, Calif. (March 16, 2022) –

Relocation driven by increased demand for Vector Laboratories’ growing areas of focus, glycomics and proteomics

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today opened its new facility in Newark, California, where it will relocate its corporate headquarters this year. The relocation i…

BURLINGAME, Calif. (February 2, 2022) –

Key appointment will support the company’s commercial growth plans to deliver proteomics and protein innovations worldwide

Vector Laboratories, the pioneer of innovative proteomic and glycomic solutions, today announced the addition of Katy Miles to its Board of Dire…

BURLINGAME, Calif. (December 14, 2021) –

Mr. Morales’ decades of financial experience in the life sciences sector will drive Vector Laboratories’ ongoing expansion strategy

Vector Laboratories, the pioneer and leader in the development and manufacture of protein labeling and detection reagents for life sciences research, today announced that Mike Morales, …

BURLINGAME, Calif. (November 16, 2021) –

Vector Laboratories, the market leader in the development and manufacture of labeling and detection reagents for biomedical research, today announced that it has promoted Pamela James, Ph.D., to the position of Vice President, Product, effective immediately. Dr. James was previously Senior Director, R&D and Operations. In her new role, she will continue to oversee research …

BURLINGAME, Calif. (September 7, 2021) –

Vector Laboratories, the market leader in the development and manufacture of labeling and detection reagents for biomedical research, today announced that it has closed a $124 million cash buyout, backed by private equity firm Thompson Street Capital Partners to accelerate its expansion into protein detection. This new funding enables Vector Laboratories to embark upon an acqui…

BURLINGAME, Calif. (November 14, 2018) –

Vector Laboratories, a Maravai LifeSciences company and leader in the development and manufacture of labeling and detection reagents for biomedical research, announced today that it has achieved ISO 9001:2015 certification. This new designation for the company certifies a high level of quality assurance and consistency and will be particularly important to Vector customers who …

BURLINGAME, Calif. (September 11, 2018) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces VECTASHIELD® Vibrance™ – antifade mounting media that delivers significant improvements to the immunofluorescence workflow. VECTASHIELD Vibrance produces increased brightness over the entire visible spectrum, including far-red fluorophore…

BURLINGAME, Calif. (June 12, 2018) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, has launched a redesigned company website, with advanced navigation and added technical resources. Users can now easily access application workflows and tools to help them select the best product for their work.

The new site also delivers an i…

BURLINGAME, Calif. (March 22, 2018) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, announced today the availability of its new five-part video training series on immunohistochemistry (IHC) online this week,

BURLINGAME, Calif. (November 13, 2017) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces the TrueVIEW™ Autofluorescence Quenching Kit, offering the first effective technique for removing unwanted fluorescence in formalin-fixed paraffin embedded (FFPE) tissue samples, blood cells and structural elements such as co…

BURLINGAME, Calif. (October 18, 2017) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, announced today the availability of a new guide for the growing field of immunofluorescence (IF). This new 32-page resource covers all aspects of IF and its implementation, including history of the technique’s development, the IF workfl…

BURLINGAME, Calif. (October 10, 2017) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, announced today that it has selected Brockville, Ontario-based MJSBioLynx as its exclusive distributor in Canada. MJSBioLynx specializes in providing high-quality products for life science researchers in protein chemistry, immunology, molecular biology a…

BURLINGAME, Calif. (October 3, 2017) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces the ImmPRESS™ Duet Double-Staining Polymer Kit for immunohistochemistry. The new kit delivers all the advantages of polymer stains including low background staining, high signal intensity and the elimination of off- target binding. The kit e…

BURLINGAME, Calif. (September 18, 2017) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, announces the publication of a new immunohistochemistry (IHC) guide, providing a comprehensive compilation of helpful tools for understanding and implementing IHC. This new 48-page guide focuses on all aspects of IHC and its implementatio…

BURLINGAME, Calif. (September 16, 2017) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, announces an exclusive distribution agreement with Shenzhen-based NeoBioscience Technology Company, a distributor of a broad range of high-quality research tools. Established in 2007, the company has offices in Shenzhen, Beijing, Shanghai…

BURLINGAME, Calif. (September 6, 2017) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces the VectaFluor™ Duet kit, offering convenient, ready-to-use immunofluorescence double labeling. This new kit is ideal for use on a wide range…

BURLINGAME, Calif. (September 5, 2016) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces a ready-to-use (RTU) animal-free blocking agent and diluent for cell- and tissue-based immunohistochemistry (IHC) and immunofluorescence. This new plant-based block is an alternative to widely used animal-based blocks such as s…

BURLINGAME, Calif. (June 15, 2016) –

Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research, introduces ImmPACT™ Vector® Red AP Substrate Kit, delivering a crisp red reaction product for studies involving immunohistochemistry, immunocytochemistry, immunofluorescence, in situ hybridization and blots. The most sensitive red alka…

BURLINGAME, Calif. (April 5, 2016) –

Maravai LifeSciences, a transformative company in the life science research market, announced today that it has acquired Vector Laboratories, a leader in the development and manufacture of labeling and detection reagents for biomedical research. The acquisition fits with Maravai LifeSciences’ goal of creating a market-leading life science business by bringing…

Media Contact

Email: [email protected]